786 related articles for article (PubMed ID: 14601692)
81. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?
D'Arena G; Taylor RP; Cascavilla N; Lindorfer MA
Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):62-8. PubMed ID: 18393924
[TBL] [Abstract][Full Text] [Related]
82. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
Lalayanni C; Stavroyianni N; Saloum R; Tsompanakou A; Anagnostopoulos A
Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
[TBL] [Abstract][Full Text] [Related]
83. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency.
Al-Ahmad M; Al-Rasheed M; Al-Muhani A
J Investig Allergol Clin Immunol; 2010; 20(3):259-62. PubMed ID: 20635793
[TBL] [Abstract][Full Text] [Related]
84. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O
J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
[TBL] [Abstract][Full Text] [Related]
85. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
[TBL] [Abstract][Full Text] [Related]
86. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
Gómez-Almaguer D; Solano-Genesta M; Tarín-Arzaga L; Herrera-Garza JL; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Jaime-Pérez JC
Blood; 2010 Dec; 116(23):4783-5. PubMed ID: 20841509
[TBL] [Abstract][Full Text] [Related]
87. Sustained remission of CIDP associated with Evans syndrome.
Knecht H; Baumberger M; Tobòn A; Steck A
Neurology; 2004 Aug; 63(4):730-2. PubMed ID: 15326255
[TBL] [Abstract][Full Text] [Related]
88. [Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune hemolytic anemia].
Wang L; Xu W; Li JY; Xie XY; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):425-8. PubMed ID: 17493362
[TBL] [Abstract][Full Text] [Related]
89. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Derumeaux H; Adoue D
Am J Hematol; 2014 Jan; 89(1):41-6. PubMed ID: 24038066
[TBL] [Abstract][Full Text] [Related]
90. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
[TBL] [Abstract][Full Text] [Related]
91. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Willis F; Marsh JC; Bevan DH; Killick SB; Lucas G; Griffiths R; Ouwehand W; Hale G; Waldmann H; Gordon-Smith EC
Br J Haematol; 2001 Sep; 114(4):891-8. PubMed ID: 11564082
[TBL] [Abstract][Full Text] [Related]
92. Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.
Aleem A
Ann Saudi Med; 2008; 28(5):382-5. PubMed ID: 18779631
[No Abstract] [Full Text] [Related]
93. Evan's syndrome complicating multicentric Castleman's disease -- dramatic response to rituximab.
Quinn JP; Gilligan OM; Horgan M
Eur J Haematol; 2004 Nov; 73(5):384-5. PubMed ID: 15458520
[No Abstract] [Full Text] [Related]
94. [Not Available].
Hbibi M; El Alaoui El Hanafi M; Kasmi Z; Ouair H; Benmiloud S; Ailal F; Hida M; Bousfiha AA
Tunis Med; 2024 Jan; 102(1):1-6. PubMed ID: 38545722
[TBL] [Abstract][Full Text] [Related]
95. [Successful rituximab treatment for acquired amegakaryocytic thrombocytopenic purpura complicated with Coombs-negative autoimmune hemolytic anemia].
Hashimoto A; Fujimi A; Kanisawa Y; Matsuno T; Okuda T; Minami S; Doi T; Ishikawa K; Uemura N; Tomaru U
Rinsho Ketsueki; 2013 Jun; 54(6):568-73. PubMed ID: 23823096
[TBL] [Abstract][Full Text] [Related]
96. [Lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia].
Zhang X; Sun J
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):236-8. PubMed ID: 24666491
[TBL] [Abstract][Full Text] [Related]
97. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
Zaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De Luca S; Ferrara F; Isola M; Baccarani M; Fanin R
Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
[TBL] [Abstract][Full Text] [Related]
98. Management of autoimmune cytopenia complicating chronic lymphocytic leukemia.
Zent CS; Shanafelt T
Leuk Lymphoma; 2009 Jun; 50(6):863-4. PubMed ID: 19455465
[No Abstract] [Full Text] [Related]
99. [Primary immunodeficiencies presenting with autoimmune cytopenias in adults].
Sève P; Broussolle C; Pavic M
Rev Med Interne; 2013 Mar; 34(3):148-53. PubMed ID: 22703729
[TBL] [Abstract][Full Text] [Related]
100. Severe Evans's syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody.
Abdel-Raheem MM; Potti A; Kobrinsky N
Ann Hematol; 2001 Sep; 80(9):543-5. PubMed ID: 11669305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
